These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 34951114)

  • 21. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
    Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
    Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
    Korzeniecki C; Priefer R
    Eur J Med Chem; 2021 Feb; 211():113006. PubMed ID: 33228976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
    Kauko O; O'Connor CM; Kulesskiy E; Sangodkar J; Aakula A; Izadmehr S; Yetukuri L; Yadav B; Padzik A; Laajala TD; Haapaniemi P; Momeny M; Varila T; Ohlmeyer M; Aittokallio T; Wennerberg K; Narla G; Westermarck J
    Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.
    Sanclemente M; Francoz S; Esteban-Burgos L; Bousquet-Mur E; Djurec M; Lopez-Casas PP; Hidalgo M; Guerra C; Drosten M; Musteanu M; Barbacid M
    Cancer Cell; 2018 Feb; 33(2):217-228.e4. PubMed ID: 29395869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitor of Differentiation-1 Sustains Mutant
    Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
    Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
    Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
    J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
    Misale S; Fatherree JP; Cortez E; Li C; Bilton S; Timonina D; Myers DT; Lee D; Gomez-Caraballo M; Greenberg M; Nangia V; Greninger P; Egan RK; McClanaghan J; Stein GT; Murchie E; Zarrinkar PP; Janes MR; Li LS; Liu Y; Hata AN; Benes CH
    Clin Cancer Res; 2019 Jan; 25(2):796-807. PubMed ID: 30327306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
    El Osta B; Behera M; Kim S; Berry LD; Sica G; Pillai RN; Owonikoko TK; Kris MG; Johnson BE; Kwiatkowski DJ; Sholl LM; Aisner DL; Bunn PA; Khuri FR; Ramalingam SS
    J Thorac Oncol; 2019 May; 14(5):876-889. PubMed ID: 30735816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma.
    Kohler J; Catalano M; Ambrogio C
    Curr Med Chem; 2018 Feb; 25(5):558-574. PubMed ID: 28554329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.
    Kitajima S; Asahina H; Chen T; Guo S; Quiceno LG; Cavanaugh JD; Merlino AA; Tange S; Terai H; Kim JW; Wang X; Zhou S; Xu M; Wang S; Zhu Z; Thai TC; Takahashi C; Wang Y; Neve R; Stinson S; Tamayo P; Watanabe H; Kirschmeier PT; Wong KK; Barbie DA
    Cancer Cell; 2018 Sep; 34(3):439-452.e6. PubMed ID: 30205046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
    Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
    Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
    Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS
    Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB
    Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
    Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in
    Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R
    Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.
    Guibert N; Ilie M; Long E; Hofman V; Bouhlel L; Brest P; Mograbi B; Marquette CH; Didier A; Mazieres J; Hofman P
    Curr Mol Med; 2015; 15(5):418-32. PubMed ID: 25941815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
    Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
    Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.